Article
DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer - Oncogene
Rating:
0.0
Views:
10
Likes:
1
Library:
1
Castration-resistant prostate cancer (CRPC) is an aggressive disease with poor prognosis, and there is an urgent need for more effective therapeutic targets to address this challenge. Here, we showed that dihydroorotate dehydrogenase (DHODH), an enzyme crucial in the pyrimidine biosynthesis pathway, is a promising therapeutic target for CRPC.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value